Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients

Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR

Bone Marrow Transplant. 2013 Feb;48(2):269-77. doi: 10.1038/bmt.2012.132. Epub 2012 Jul 9

Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED.

Biol Blood Marrow Transplant. 2012 Feb;18(2):257-64. Epub 2011 Jul 4

Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.

Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S

J Immunother. 2011 Jan;34(1):100-6

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P.

J Clin Oncol. 2009 Jun 20;27(18):3036-43. Epub 2009 May 4.

Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells

David J. Betting, Xi Y. Mu, Kamran Kafi, Desmond McDonnel, Francisco Rosas, Daniel P. Gold, and John M. Timmerman. 

Vaccine. 2009 January 7; 27(2): 250–259

Prolonged idiotypic vaccination against follicular lymphoma

Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M.

Leuk Lymphoma. 2009 Jan;50(1):47-53

Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma

John M. Timmerman, Julie M. Vose, Debra K. Czerwinski, Wen-Kai Weng, Diane Ingolia, Martha Mayo, Dan W. Denney, and Ronald Levy.  

Leuk Lymphoma. 2009 January; 50(1): 37–46.

Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines

Kamran Kafi, David J. Betting, Reiko E. Yamada, Michael Bacica, Kristopher K. Steward, and John M. Timmerman. 

Mol Immunol. 2009 January; 46(3): 448–456

Developing idiotype vaccines for lymphoma: From preclinical studies to Phase III clinical trials

Hyun Jun Park and Sattva S. Neelapu, M.D.  

Br J Haematol. 2008 June; 142(2): 179–191

Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.

Koumarianou A, Kountourakis P, Economopoulos T.

J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):230-2. Epub 2008 Mar 7.